Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOGICAN
2024-512999-35-00Phase 2Authorised
- Sponsor
- Unicancer
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of trifluridine + tipiracil, nivolumab and FOLFOX in gastric adenocarcinoma, esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (4 arms), sponsored by Unicancer. Primary endpoint: Progression-free survival. Planned start Jun 2024; status: authorised.
02
Drugs
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2024-512999-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512999-35-00.